Skip to main content
Download PDF

KIF14 affects cell cycle arrest and cell viability in cervical cancer by regulating the p27Kip1 pathway

World Journal of Surgical Oncology volume 20, Article number: 125 (2022) Cite this article

Abstract

Background

Cervical cancer is a kind of malignant gynecological tumor. The first choice for treating cervical cancer is still a combination of surgery and chemoradiotherapy, but the 5-year survival rate remains poor. Therefore, researchers are trying to find new ways to diagnose and treat cervical cancer early.

Methods

The expression level of KIF14 in cells and tissues was determined via qRT–PCR. The ability of the cells to proliferate, migrate, and invade was examined using CCK-8 assay kits, colony formation assays, and Transwell chambers. The expression levels of Cyclin D1, Cyclin B1, p21, and p27 were also detected using western blot assays.

Results

The results suggested that p27 is a key regulatory factor in the KIF14-mediated regulation of the cell cycle. In addition, KIF14 knockdown promotes malignancy in cervical cancer cells by inhibiting p27 degradation, resulting in cell cycle arrest.

Conclusions

KIF14 is an oncogene in cervical cancer, and knocking down KIF14 causes cell cycle arrest by inhibiting p27 degradation, thus affecting cell viability, proliferation, and migration. These results provide a potential therapeutic target for cervical cancer.

Background

Cervical cancer is one of the most common malignant gynecological tumors: it accounts for approximately 270,000 deaths every year, ranking fourth in cancer mortality among females globally [1, 2]. It has become a prominent public health problem and seriously threatens the health of women worldwide [3]. Advances in screening technology and the use of human papillomavirus (HPV) vaccines in clinical practice have resulted in great progress in the prevention and treatment of cervical cancer. However, due to the cost and technical requirements of screening, these tests cannot be widely used in developing countries. In addition, although the combination of surgery and chemoradiotherapy is still the first choice for cervical cancer treatment, the 5-year survival rate after treatment is less than 40% [4, 5]. It is still vital to study the pathogenesis of cervical cancer and find markers that predict specific therapeutic targets.

Kinesin is a molecular motor that performs its biological function by moving along microtubules [6]. It modulates the transport of biological macromolecules to ensure the basic activity of cells, plays a role in the regulation of some intracellular molecular signaling pathways, and extensively participates in many diseases [7, 8]. KIF14 belongs to the kinesin superfamily and participates in chromosome separation and cytokinesis [9, 10]. Studies have found that KIF14 is associated with the occurrence of various cancers [11,12,13]. Therefore, this study aimed to analyze the possible relationship between KIF14 and cervical cancer.

The cell cycle is the center of cellular activity, and the abnormal regulation of the cell cycle is closely associated with tumor development and malignancy [14], the inactivation of suppressor oncogenes, and the alteration of apoptosis-regulating genes or mutated genes [15, 16]. Regardless of the cause, the ultimate manifestation of various cancers is the abnormal growth of normal cells. Cell cycle regulation is the most common molecular mechanism underlying tumor formation [17]. p27Kip1 (hereafter p27) is a member of the cyclin-dependent kinase inhibitor (CDKI) family. It suppresses cyclin/CDK complex activity and arrests the cell cycle [18]. Moreover, decreases in p27 are positively correlated with the rate of apoptosis [19].

Here, we verified the role and regulatory mechanism of KIF14 in cervical cancer. Collectively, our findings reveal the functional mechanism by which KIF14 regulates the cell cycle during tumorigenesis, thus providing potential value in the treatment of cervical cancer.

Materials and methods

Cell culture

The human cervical cancer cell lines HeLa, Ca Ski, and SiHa and the cervical epithelial cell lines H8 and HUCEC (Institute of Cell Biology, China) were cultured in RPMI-1640 medium (HyClone, USA) supplemented with 10% FBS (Gibco, USA). All the cell lines were maintained in a humidified incubator containing 5% CO2 at 37 °C.

Tissue sample collection

Human cervical tissue samples and normal cervical tissue samples were collected by professionals and preserved in the specimen bank of the Cancer Prevention and Treatment Institute of the Affiliated Cancer Hospital of Xinjiang Medical University.

Cell transfection

Cells were seeded into 6-well plates and cultured as described above. The culture medium was replaced after 6 h. For transient silencing, cells were transfected with KIF14 siRNA or control siRNA duplexes (Sangon Bioengineering, China). The details of the interference sequences are as follows: siKIF14-1: 5′-GCCCGUUUAAUAGUCAACAUUTT-3′; siKIF14-2: 5′- GCUGCAUUUGAAGUCGGAUAUTT-3′; siKIF14-3: 5′-CGGCAAGAAAUAACAUCCUUATT-3′; and siNC: 5′-UUCUCCGAACGUGUCACGUTT-3′. Cells were transfected with Lipofectamine 8000 (Beyotime, China) according to the manufacturer’s instructions.

qRT–PCR

Tissue and cell samples were lysed with TRIzol (Invitrogen, USA). A TaqMan Reverse Transcription kit (Takara, Japan) was used to reverse transcribe cDNA. Reactions were run on an ABI 7000 Thermocycler (Applied Biosystems, USA). The expression of each gene was calculated using the 2−ΔΔCt method. The following primer sequences were used: KIF14 forward, 5′-CGGAACAAGCAAACCAAAGGAGTG-3′, reverse, 5′-GCAGCGGGACTAATCGTAGCAATC-3′; Cyclin D1 forward, 5′-CAGAGGCGGAGGAGAACAAA-3′, reverse, 5′-ATGGAGGGCGGATTGGAA-3′; Cyclin B1 forward, 5′-ATGCAGCACCTGGCTAAGAA-3′, reverse, 5′-TACACCTTTGCCACAGCCTT-3′; and GAPDH forward, 5′- GGGTGATGCAGGTGCTACTT-3′; reverse, 5′-GCACTTGGGGCAGAGATGAT-3′.

Western blot

Cells were collected and lysed with RIPA buffer (Beyotime, China). Lysates (20–30 μg) were added to SDS–PAGE gels and transferred to PVDF membranes. Blots were probed with primary antibodies (Cell Signaling Technology, USA) against KIF14, Cyclin D1, Cyclin B1, p21, or p27, overnight at 4 °C. Membranes were then incubated with the corresponding HRP-conjugated secondary antibodies for 1 h. The blots were subsequently detected with an ECL Kit (Beyotime, China). Protein blotting images were analyzed using ImageJ software (NIH, USA).

Cell viability

The cells in each transfected group were digested with a routine trypsin protocol and added to serum-free medium that had been precooled at 4 °C. After centrifugation, a 100-μl cell suspension was prepared in a 96-well plate. At 24 h, 48 h, and 72 h, 10 μl CCK8 solution (Dojindo, Japan) was added to each well. The absorbance at 450 nm was measured with a microplate analyzer (Biotek Instruments, USA).

Cell migration and invasion assays

To assess cell migration and invasion, Transwell assays were performed as previously described [20]. Forty-eight hours after transfection, 5 × 104 cells were resuspended in serum-free media and then inoculated in the upper chamber. For the invasion assay, Matrigel (BD Biosciences, USA) was added to the upper chamber. Medium with 10% FBS was added to the lower chambers. After 24 h, the cells were fixed and stained with 0.5% crystal violet (Solarbio, China) for 20 min. A microscope (Leica Microsystems, Canada) was used to capture images.

Statistical analysis

All the results were analyzed using the SPSS 21.0 software (IBM, USA). The data are from at least three independent repeats and are shown as the mean ± SD. Statistical tests were performed using Dunnett’s t test and one-way analysis of variance (ANOVA) for more than two groups. P < 0.05 was considered statistically significant.

Results

KIF14 is highly expressed in cervical cancer

RT–qPCR showed that the KIF14 level was upregulated in 20 cervical cancer tissues compared to 10 normal tissues (Fig. 1A). In addition, the KIF14 level in cervical cancer cells was higher than that in cervical cells (Fig. 1B, C). Therefore, we concluded that KIF14 was upregulated in cervical cancer.

Fig. 1
figure 1

KIF14 is highly expressed in cervical cancer. A KIF14 levels in cervical cancer tissues were detected via qRT–PCR. B, C The relative mRNA and protein levels of KIF14 in cervical cancer cells; cervical cells were assessed via RT–qPCR and western blot assays. *p < 0.05, **p < 0.01, and ***p < 0.001

Full size image

KIF14 knockdown inhibits cell proliferation, migration and invasion

To study the effects of KIF14 in cervical cancer, three pairs of siRNA sequences, siKIF14-1, siKIF14-2, and siKIF14-3, were designed against the target KIF14 gene sequence, and siNC was designed for the control transfection group. Then, we verified the transfection efficiency and detected the levels of KIF14 mRNA and protein after transiently transfecting HeLa and siHa cells with the interference sequences (Fig. 2A, B). A CCK-8 assay showed that the cell viability in the interference group was significantly inhibited (Fig. 2C). The results of a clone formation experiment are shown in Fig. 2D. Transwell experiments were used to detect cell migration and passage through Matrigel in the control and interference groups. Interfering with KIF14 expression significantly inhibited the migration and invasion of cervical cancer cells (Fig. 2E, F).

Fig. 2
figure 2

KIF14 knockdown inhibits cell proliferation, migration and invasion. HeLa and siHa cells were transfected with siNC, siKIF14-1, siKIF14-2, or siKIF14-3 for 24 h. A, B Relative mRNA and protein levels of KIF14 in cervical cancer cells from the interference groups. C CCK-8 assays detected the cell viability in the KIF14 interference groups. D A clone formation assay was used to detect the proliferative ability. E Detection of cell migration ability. Scale bar = 100 μm. F Detection of cell invasion ability. Scale bar = 100 μm. *p < 0.05, **p < 0.01, and ***p < 0.001

Full size image

KIF14 overexpression promotes cell proliferation, migration, and invasion

The effect of KIF14 overexpression on cervical cancer cells was further studied, and we first verified the overexpression efficiency in HeLa and siHa cells. The relative mRNA expression of KIF14 was higher in the KIF14 OE group than that in the NC group (Fig. 3A). In addition, the trends in protein and mRNA expression were the same (Fig. 3B). A CCK-8 assay showed that cell proliferation was significantly increased in the KIF14 OE group (Fig. 3C). Clone formation and Transwell assays suggested that KIF14 overexpression could significantly promote the proliferation, migration, and invasion of cervical cancer cells (Fig. 3D–F).

Fig. 3
figure 3

KIF14 overexpression promotes cell proliferation, migration, and invasion. HeLa and siHa cells were transfected with NC OE or KIF14-3 OE for 24 h. A, B The transfection efficiency of KIF14 OE C. Cell viability was detected via a CCK-8 assay. D A clone formation assay detected the proliferation ability. E Detection of cell migration ability. Scale bar = 100 μm. F Detection of cell invasion ability. Scale bar = 100 μm. *p < 0.05, **p < 0.01, and ***p < 0.001

Full size image

KIF14 knockdown results in cervical cancer cell cycle arrest

There is a close relationship between the cell cycle and tumor progression. When the regulatory mechanism of the cell cycle is damaged, normal cell growth can be uncontrolled; thus, cells can transform into tumor cells. Cells were divided into siNC, siKIF14, NC OE, and KIF14 OE groups. As shown in Fig. 4A, KIF14 inhibition suppressed KIF14, Cyclin D1, and Cyclin B1 levels and increased p27 levels. While overexpressing KIF14 in HeLa cells increased the levels of KIF14, Cyclin D1, and Cyclin B1, it reduced the p27 protein level. Interestingly, neither the knockdown nor the overexpression of KIF14 affected p27 mRNA expression levels, which was inconsistent with the changes in protein levels (Fig. 4B). These data indicated that p27 might be regulated at the level of protein stability. Thus, 2 μg/ml cycloheximide was added to assess p27 stability. As shown in Fig. 4C, KIF14 knockdown inhibited p27 degradation.

Fig. 4
figure 4

KIF14 knockdown results in cervical cancer cell cycle arrest. HeLa cells were transfected with si-NC, si-KIF14, NC OE, or KIF14 OE for 24 h. A The KIF14 and cyclin-associated protein levels were detected via western blot. B KIF14 knockdown or overexpression and the mRNA levels of Cyclin D1, Cyclin B1, p21, and p27. C HeLa cells were transfected with si-NC or si-KIF14 for 24 h and then treated with 2 μg/ml cycloheximide for 0 h, 0.5 h, 1 h, and 3 h. KIF14 knockdown inhibited p27 degradation. *p < 0.05, **p < 0.01, and ***p < 0.001

Full size image

KIF14 knockdown arrests the cell cycle by inhibiting p27 degradation

To further verify the regulatory mechanism by which KIF14 affects the cell cycle by regulating p27 degradation, cells were transfected with siKIF14, p27 KD, or siKIF14+p27 KD. Western blot assays showed that p27 KD suppressed p27 expression and increased Cyclin D1 and Cyclin B1 levels (Fig. 5A). Cyclin D1 and Cyclin B1 levels were decreased and p27 levels were increased when the cells were transfected with siKIF14, but the trend was reversed when the cells were transfected with siKIF14 + p27 KD (Fig. 5A). Functionally, p27 KD promoted cell viability, clone formation, migration and invasion; siKIF14 suppressed cell viability, clone formation, migration and invasion; and siKIF14 + p27 KD reversed the effects of siKIF14 (Fig. 5B–E).

Fig. 5
figure 5

KIF14 knockdown arrests the cell cycle by inhibiting p27 degradation. HeLa cells were divided into siNC, siKIF14, p27 KD, and siKIF14+p27 KD groups. A The trends in the changes associated with KIF14 and cyclin-associated protein expression levels were reversed in the si-KIF14+p27 KD group compared with the si-KIF14 group. B Cell viability as detected via CCK-8 assays. C A clone formation assay was used to detect the proliferation ability. D Detection of cell migration ability. Scale bar = 100 μm. E. Detection of cell invasion ability. Scale bar = 100 μm. *p < 0.05, **p < 0.01, and ***p < 0.001

Full size image

Discussion

More than half a century of effort has enabled the prevention and treatment of cervical cancer [21]. However, cervical cancer is still an important public health problem, especially in developing countries and regions. Advanced cases and recurrent cases after treatment are not uncommon [22]. Strategies to improve patient prognosis and quality of life deserve further study. It is reported that abnormal expression of important genes and alterations of signaling pathways are associated with cancer pathogenesis [23, 24]. For instance, Qin F et al. revealed a novel angiogenesis subtype classification in squamous cell carcinoma [23]. Li S et al. screened six prognostic hub genes by weighted gene co-expression network analysis (WGCNA) combined with LASSO Cox-PH analysis, which provided a new strategy for targeted therapy of cervical cancer [24]. The study aimed to explore the molecular mechanism of cervical cancer and find new tumor markers and biological methods to treat tumors .

Increasing evidence demonstrated that gene therapy is a promising candidate in the treatment of cancers [25, 26]. For instance, Lu X et al. found that targeting IGF1 by miR-186-3p suppressed tumorigenesis of cervical cancer [25]. Besides, Zou H et al. clarified that circ_0018289 inhibition might be a promising point for the development of novel anti-tumor strategies against cervical cancer [26]. KIF14 has been proven by numerous researchers to be an important oncogene in many cancers [27,28,29,30]. It can be used as a marker for detecting paclitaxel resistance during the treatment of ovarian cancer [31]. Therefore, as KIF14 becomes an increasingly important target for cancer therapy and prognostic monitoring markers, it is crucial to understand the mechanisms regulating its gene [32]. Therefore, this study aimed to observe KIF14 expression in cervical cancer and further explore the influence of changes in its expression on the proliferation, invasion, migration, and cycle of cervical cancer cells.

In this study, the KIF14 level in cervical cancer tissue was significantly upregulated. These results suggested that KIF14 has great potential as a diagnostic and therapeutic target. Next, to explore the role of KIF14, we designed and synthesized three interference sequences targeting KIF14 and transiently transfected HeLa and SiHa cervical cancer cells. We observed transfection by using fluorescent groups coupled with the interference sequences and confirmed that the transfection efficiency met the requirements. The results showed that the three designed interference sequences could effectively interfere with the level of KIF14 at the gene level, but only SiKIF14-2 and SiKIF14-3 had significant interference efficiency at the protein level. When the expression of KIF14 was disturbed, cell proliferation, migration, and invasion were significantly inhibited. The results of these in vitro experiments all indicate that KIF14 is indeed a potential oncogene.

Some researchers have speculated that KIF14 is associated with cytokinesis and plays a key role in cell cycle arrest [33, 34]. Thus, we detected whether the cyclin-related proteins Cyclin D1, Cyclin B1, p21, and p27 were overexpressed or knocked down. After interference with the SiKIF14-2 sequence, the expression of Cyclin D1 and Cyclin B1 decreased, while the expression of p27 protein increased in HeLa cells; the trend in the change was the opposite in the case of overexpression. However, the specific molecules that interact with KIF14 in cells and the molecular mechanisms that inhibit cell growth need to be further studied and determined. We found that p27 mRNA levels did not change, which contrasted with the change in protein level. We speculated that p27 might be regulated at the level of protein stability. We compared the stability of p27 transfected with or without SiKIF14 using cycloheximide to inhibit protein synthesis. These results collectively clarified that KIF14 inhibition arrested the cell cycle by suppressing p27 degradation. Furthermore, the above conclusions were verified by rescue experiments.

Conclusions

In conclusion, the KIF14 level is upregulated in cervical cancer, and KIF14 knockdown suppresses cell proliferation, migration, and invasion, resulting in cell cycle arrest by inhibiting p27 degradation.

Availability of data and materials

The data used to support the findings of this study are available from the corresponding author upon request.

References

  1. LaVigne AW, Triedman SA, Randall TC, Trimble EL, Viswanathan AN. Cervical cancer in low and middle income countries: addressing barriers to radiotherapy delivery. Gynecol Oncol Rep. 2017;22:16–20.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl_4): iv72-iv83.

  3. Schiffman M. Cervical cancer screening: Epidemiology as the necessary but not sufficient basis of public health practice. Prev Med. 2017;98:3–4.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Menderes G, Black J, Schwab CL, Santin AD. Immunotherapy and targeted therapy for cervical cancer: an update. Exp Rev Anticancer Ther. 2016;16(1):83–98.

    Article  CAS  Google Scholar 

  5. Bendifallah S, de Foucher T, Bricou A, Ouldamer L, Lavoue V, Varinot J, et al. Cervical cancer recurrence: proposal for a classification based on anatomical dissemination pathways and prognosis. Surg Oncol. 2019;30:40–6.

    Article  PubMed  Google Scholar 

  6. Niwa S. Kinesin superfamily proteins and the regulation of microtubule dynamics in morphogenesis. Anat Sci Int. 2015;90(1):1–6.

    Article  CAS  PubMed  Google Scholar 

  7. Zhong A, Tan FQ, Yang WX. Chromokinesin: kinesin superfamily regulating cell division through chromosome and spindle. Gene. 2016;589(1):43–8.

    Article  CAS  PubMed  Google Scholar 

  8. Gu S, Liang H, Qi D, Mao L, Mao G, Qian L, et al. Knockdown of KIF26B inhibits breast cancer cell proliferation, migration, and invasion. OncoTarget Ther. 2018;11:3195–203.

    Article  Google Scholar 

  9. Cai S, Weaver LN, Ems-McClung SC, Walczak CE. Proper organization of microtubule minus ends is needed for midzone stability and cytokinesis. Curr Biol. 2010;20(9):880–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zhu C, Zhao J, Bibikova M, Leverson JD, Bossy-Wetzel E, Fan JB, et al. Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol Biol Cell. 2005;16(7):3187–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Corson TW, Gallie BL. KIF14 mRNA expression is a predictor of grade and outcome in breast cancer. Int J Cancer. 2006;119(5):1088–94.

    Article  CAS  PubMed  Google Scholar 

  12. Thériault BL, Basavarajappa HD, Lim H, Pajovic S, Gallie BL, Corson TW. Transcriptional and epigenetic regulation of KIF14 overexpression in ovarian cancer. PLoS One. 2014;9(3):e91540.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Thériault BL, Cybulska P, Shaw PA, Gallie BL, Bernardini MQ. The role of KIF14 in patient-derived primary cultures of high-grade serous ovarian cancer cells. J Ovarian Res. 2014;7:123.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Wiman KG, Zhivotovsky B. Understanding cell cycle and cell death regulation provides novel weapons against human diseases. J Intern Med. 2017;281(5):483–95.

    Article  CAS  PubMed  Google Scholar 

  15. Lou X, Zhang J, Liu S, Xu N, Liao DJ. The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis. Cell Cycle (Georgetown, Tex). 2014;13(11):1677-1693.

  16. Vicente-Dueñas C, Romero-Camarero I, Cobaleda C, Sánchez-García I. Function of oncogenes in cancer development: a changing paradigm. EMBO J. 2013;32(11):1502–13.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Li J, Stanger BZ. Cell cycle regulation meets tumor immunosuppression. Trend Immunol. 2020;41(10):859–63.

    Article  CAS  Google Scholar 

  18. Abbastabar M, Kheyrollah M, Azizian K, Bagherlou N, Tehrani SS, Maniati M, et al. Multiple functions of p27 in cell cycle, apoptosis, epigenetic modification and transcriptional regulation for the control of cell growth: a double-edged sword protein. DNA Repair. 2018;69:63–72.

    Article  CAS  PubMed  Google Scholar 

  19. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol. 1999;154(2):313–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hu YP, Wu ZB, Jiang L, Jin YP, Li HF, Zhang YJ, et al. STYK1 promotes cancer cell proliferation and malignant transformation by activating PI3K-AKT pathway in gallbladder carcinoma. Int J Biochem Cell Biol. 2018;97:16–27.

    Article  CAS  PubMed  Google Scholar 

  21. Vu M, Yu J, Awolude OA, Chuang L. Cervical cancer worldwide. Curr Probl Cancer. 2018;42(5):457–65.

    Article  PubMed  Google Scholar 

  22. Shrestha AD, Neupane D, Vedsted P, Kallestrup P. Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review. Asian Pac J Cancer Prev. 2018;19(2):319–24.

    PubMed  PubMed Central  Google Scholar 

  23. Li S, Han F, Qi N, Wen L, Li J, Feng C, et al. Determination of a six-gene prognostic model for cervical cancer based on WGCNA combined with LASSO and Cox-PH analysis. World J Surg Oncol. 2021;19(1):277.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Qin F, Lin S, Deng K, Qin J, Xu Z, Yuan L, et al. Comprehensive analysis of angiogenesis subtype of squamous cell carcinoma. World J Surg Oncol. 2021;19(1):275.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Lu X, Song X, Hao X, Liu X, Zhang X, Yuan N, et al. MiR-186-3p attenuates tumorigenesis of cervical cancer by targeting IGF1. World J Surg Oncol. 2021;19(1):207.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Zou H, Chen H, Liu S, Gan X. Identification of a novel circ_0018289/miR-183-5p/TMED5 regulatory network in cervical cancer development. World J Surg Oncol. 2021;19(1):246.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Wang Q, Wang L, Li D, Deng J, Zhao Z, He S, et al. Kinesin family member 14 is a candidate prognostic marker for outcome of glioma patients. Cancer Epidemiol. 2013;37(1):79–84.

    Article  CAS  PubMed  Google Scholar 

  28. Thériault BL, Pajovic S, Bernardini MQ, Shaw PA, Gallie BL. Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer. Int J Cancer. 2012;130(8):1844–54.

    Article  PubMed  Google Scholar 

  29. Markowski J, Tyszkiewicz T, Jarzab M, Oczko-Wojciechowska M, Gierek T, Witkowska M, et al. Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma. Eur Arch Otorhinolaryngol. 2009;266(10):1501–7.

    Article  PubMed  Google Scholar 

  30. Corson TW, Zhu CQ, Lau SK, Shepherd FA, Tsao MS, Gallie BL. KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. Clin Cancer Res. 2007;13(11):3229–34.

    Article  CAS  PubMed  Google Scholar 

  31. Ehrlichova M, Mohelnikova-Duchonova B, Hrdy J, Brynychova V, Mrhalova M, Kodet R, et al. The association of taxane resistance genes with the clinical course of ovarian carcinoma. Genomics. 2013;102(2):96–101.

    Article  CAS  PubMed  Google Scholar 

  32. Jun DY, Park HS, Lee JY, Kim YH. Regulation of the human mitotic centromere-associated kinesin (MCAK) promoter by the transcription factors Sp1 and E2F1. Biochim Biophys Acta. 2008;1779(5):356–61.

    Article  CAS  PubMed  Google Scholar 

  33. Gruneberg U, Neef R, Li X, Chan EH, Chalamalasetty RB, Nigg EA, et al. KIF14 and citron kinase act together to promote efficient cytokinesis. J Cell Biol. 2006;172(3):363–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Carleton M, Mao M, Biery M, Warrener P, Kim S, Buser C, et al. RNA interference-mediated silencing of mitotic kinesin KIF14 disrupts cell cycle progression and induces cytokinesis failure. Mol Cell Biol. 2006;26(10):3853–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Second Affiliated Hospital of Xinjiang Medical University, Nanhu Road, Urumqi, Xinjiang, 830011, China

    Jie Zhang, Gulimire Buranjiang, Zuohelaguli Mutalifu & Hua Jin

  2. Department of Obstetrics and Gynecology, Second Affiliated Hospital of Xinjiang Medical University, Nanhu Road, Urumqi, Xinjiang, 830063, China

    Liyan Yao

Authors
  1. Jie Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gulimire Buranjiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zuohelaguli Mutalifu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hua Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Liyan Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JZ and LY conceived of and designed the study and drafted the manuscript. JZ, GB, ZM, and HJ collected, analyzed, and interpreted the data. JZ and GB revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Liyan Yao.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the ethics committee of the Cancer Hospital of Xinjiang Medical University, China.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, J., Buranjiang, G., Mutalifu, Z. et al. KIF14 affects cell cycle arrest and cell viability in cervical cancer by regulating the p27Kip1 pathway. World J Surg Onc 20, 125 (2022). https://doi.org/10.1186/s12957-022-02585-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12957-022-02585-3

Keywords

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us